Inventor · disambiguated record
Ivan Ho Chan
Also filed as: CHAN IVAN · CHAN IVAN HO
12 granted patents·12 pending applications·42 citations·filing 2014–2025
88Inventor score
Top patents by PatentIndex Score
24 records- 0194US11253547B2CD19-directed chimeric antigen receptors and uses thereof in immunotherapyNKARTA INC·Filed 2020·Granted Feb 22, 2022·11 cites·19 claims
- 0294US11154575B2Cancer immunotherapy using CD19-directed chimeric antigen receptorsNKARTA INC·Filed 2020·Granted Oct 26, 2021·10 cites·25 claims
- 0394US11141436B2Immune cells engineered to express CD19-directed chimeric antigen receptors and uses thereof in immunotherapyNKARTA INC·Filed 2020·Granted Oct 12, 2021·8 cites·16 claims
- 0489US12398187B2CD19-directed chimeric antigen receptors and uses thereof in immunotherapyNKARTA INC·Filed 2022·Granted Aug 26, 2025·1 cites·24 claims
- 0588US12012458B2Genetically modified natural killer cells for CD70-directed cancer immunotherapyNKARTA INC·Filed 2021·Granted Jun 18, 2024·2 cites·26 claims
- 0686US10195274B2Method of modulating a chimeric antigen receptor t cell immune response by administering IL-10ARMO BIOSCIENCES INC·Filed 2018·Granted Feb 5, 2019·4 cites·28 claims
- 0777US10398761B2Methods of using combinations of PEG-IL-10 and IL-15 for treating cancersARMO BIOSCIENCES INC·Filed 2016·Granted Sep 3, 2019·1 cites·20 claims
- 0876US10293043B2Methods of lowering serum cholesterolARMO BIOSCIENCES INC·Filed 2015·Granted May 21, 2019·2 cites·26 claims
- 0976US10010588B2Methods of using pegylated interleukin-10 for treating hyperlipidemiaARMO BIOSCIENCES INC·Filed 2014·Granted Jul 3, 2018·2 cites·15 claims
- 1075US2025296970A1Cd19-directed chimeric antigen receptors and uses thereof in immunotherapyNKARTA INC·Filed 2025·Application pending·0 cites
- 1174US10618970B2Method of treating cancer with IL-10 and antibodies that induce ADCCARMO BIOSCIENCES INC·Filed 2016·Granted Apr 14, 2020·1 cites·18 claims
- 1271US2024360234A1Genetically modified natural killer cells for cd70-directed cancer immunotherapyNKARTA INC·Filed 2024·Application pending·0 cites
- 1366US2019099487A1Methods of using interleukin-10 for treating diseases and disordersARMO BIOSCIENCES INC·Filed 2018·Application pending·0 cites
- 1461US2025339528A1Selection of optimal cell donors and methods and compositions for enhanced expansion and cytotoxicity of donor cellsNKARTA INC·Filed 2022·Application pending·0 cites
- 1559US2016361415A1Methods of Using Interleukin-10 for Treating Diseases and DisordersARMO BIOSCIENCES INC·Filed 2016·Application pending·0 cites
- 1659US2023390392A1Multiplex gene edited cells for cd70-directed cancer immunotherapyNKARTA INC·Filed 2023·Application pending·0 cites
- 1757US11413332B2Methods of using interleukin-10 for treating diseases and disordersLILLY CO ELI·Filed 2014·Granted Aug 16, 2022·0 cites·20 claims
- 1854US2022411754A1Methods and compositions for enhanced expansion and cytotoxicity of natural killer cellsNKARTA INC·Filed 2020·Application pending·0 cites
- 1952US2024335536A1Methods of engineering immune cells for enhanced potency and persistence and uses of engineered cells in immunotherapyNKARTA INC·Filed 2021·Application pending·0 cites
- 2050US2018333464A1Methods of using interleukin-10 for treating diseases and disordersARMO BIOSCIENCES INC·Filed 2018·Application pending·0 cites
- 2146US11814679B2Interleukin-10 production of antigen-specific CD8+ T cells and methods of use of sameLILLY CO ELI·Filed 2017·Granted Nov 14, 2023·0 cites·13 claims
- 2246US2022233593A1Combinations of engineered natural killer cells and engineered t cells for immunotherapyNKARTA INC·Filed 2020·Application pending·0 cites
- 2344US2018369337A1Methods of Using Interleukin-10 for Treating Diseases and DisordersARMO BIOSCIENCES INC·Filed 2016·Application pending·0 cites
- 2439US2018360977A1Interleukin-15 Compositions and Uses ThereofARMO BIOSCIENCES INC·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Ivan Ho Chan files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →